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Abstract
Background: Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s
disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such as
dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD), is less well established. We aimed to
determine the diagnostic utility of an extended panel of CSF biomarkers to differentiate AD from a range of other
neurodegenerative dementias.
Methods: We used immunoassays to measure conventional CSF markers of amyloid and tau pathology (amyloid beta
(Aβ)1–42, total tau (T-tau), and phosphorylated tau (P-tau)) as well as amyloid processing (AβX-38, AβX-40, AβX-42,
soluble amyloid precursor protein (sAPP)α, and sAPPβ), large fibre axonal degeneration (neurofilament light chain
(NFL)), and neuroinflammation (YKL-40) in 245 patients with a variety of dementias and 30 controls. Patients fulfilled
consensus criteria for AD (n = 156), DLB (n = 20), behavioural variant frontotemporal dementia (bvFTD; n = 45),
progressive non-fluent aphasia (PNFA; n = 17), and semantic dementia (SD; n = 7); approximately 10% were pathology/
genetically confirmed (n = 26). Global tests based on generalised least squares regression were used to determine
differences between groups. Non-parametric receiver operating characteristic (ROC) curves and area under the curve
(AUC) analyses were used to quantify how well each biomarker discriminated AD from each of the other diagnostic
groups (or combinations of groups). CSF cut-points for the major biomarkers found to have diagnostic utility were
validated using an independent cohort which included causes of AD (n = 104), DLB (n = 5), bvFTD (n = 12), PNFA
(n = 3), SD (n = 9), and controls (n = 10).
Results: There were significant global differences in Aβ1–42, T-tau, T-tau/Aβ1–42 ratio, P-tau-181, NFL, AβX-42, AβX-42/
X-40 ratio, APPα, and APPβ between groups. At a fixed sensitivity of 85%, AβX-42/X-40 could differentiate AD from
controls, bvFTD, and SD with specificities of 93%, 85%, and 100%, respectively; for T-tau/Aβ1–42 these specificities were
83%, 70%, and 86%. AβX-42/X-40 had similar or higher specificity than Aβ1–42. No biomarker or ratio could differentiate
AD from DLB or PNFA with specificity > 50%. Similar sensitivities and specificities were found in the independent
validation cohort for differentiating AD and other dementias and in a pathology/genetically confirmed sub-cohort.
(Continued on next page)
* Correspondence: j.schott@ucl.ac.uk
†Equal contributors
1Dementia Research Centre, UCL Institute of Neurology, 8–11 Queen Square,
London WC1N 3BG, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Paterson et al. Alzheimer's Research & Therapy  (2018) 10:32 
https://doi.org/10.1186/s13195-018-0361-3
(Continued from previous page)
Conclusions: CSF AβX-42/X-40 and T-tau/Aβ1–42 ratios have utility in distinguishing AD from controls, bvFTD, and SD.
None of the biomarkers tested had good specificity at distinguishing AD from DLB or PNFA.
Keywords: Cerebrospinal fluid, Biomarkers, Alzheimer’s disease, Differential diagnosis
Background
Cerebrospinal fluid (CSF) biomarkers are increasingly
used to support a diagnosis of Alzheimer’s disease (AD).
CSF amyloid beta (Aβ)1–42, total tau (T-tau), and phos-
phorylated tau (P-tau) have utility in differentiating AD
from controls and in predicting conversion from mild
cognitive impairment (MCI) to AD dementia [1, 2].
Consequently, these measures are included in clinical [3]
and research diagnostic criteria [4].
A variety of other CSF measures relevant to neurode-
generation are now available. These include markers of
amyloid processing (AβX-38, AβX-40, AβX-42, soluble
amyloid precursor protein (sAPP)α, and sAPPβ), large
fibre axonal degeneration (neurofilament light chain
(NFL)), and neuroinflammation (chitinase-3-like protein
1, also known as YKL-40). The AβX-42/X-40 ratio rather
than Aβ1–42 alone may correct for inter-individual dif-
ferences in amyloid production [5] and may improve
clinical diagnostic specificity [6]. Meta-analytical data
confirm that YKL-40 and NFL are elevated in clinically
diagnosed AD CSF compared with controls [2].
While most prior studies have focussed on distinguish-
ing patients with AD from controls or predicting MCI
conversion to AD, a major challenge in clinical practice
is to distinguish AD from other neurodegenerative disor-
ders, including frontotemporal dementia (FTD), demen-
tia with Lewy bodies (DLB), semantic dementia (SD),
and progressive non-fluent aphasia (PNFA). Here, the
role of CSF biomarkers is much less well established.
The principal aims of this study were to determine
the diagnostic utility of an extended panel of CSF
biomarkers (including two biomarker ratios) both in-
dividually and in models incorporating multiple bio-
markers to distinguish AD from a range of other
primary neurodegenerative dementias in clinical prac-
tice, and to validate diagnostic cut-points using a sec-
ond, independent cohort.
Methods
The study was conducted in accordance with relevant
clinical research regulations, and with ethical approvals
in place (Queen Square ethics committee approval refer-
ence numbers 13 LO 1155 and 12 LO 1504). Written in-
formed consent was obtained from participants where
appropriate.
Two independent cohorts were studied. A test cohort
was used to estimate cut-points and to determine the
diagnostic utility of each biomarker for differentiating
AD from the other groups. A validation cohort was then
used to assess the sensitivity and specificity of these cut-
points to distinguish AD from all other subjects, from
controls, and from other dementias.
Test cohort
We included individuals referred to the Queen Square
Specialist Cognitive Disorders service who had a diag-
nostic CSF examination between 1 January 2008 and 1
January 2012. Without knowledge of the CSF result,
electronic patient records were interrogated to deter-
mine the pre-lumbar puncture (LP) diagnosis, most re-
cent clinical diagnosis, time from earliest symptom
(reported by individual or their family/caregiver) to LP,
mini-mental state examination (MMSE) score at LP, and
time from LP to most recent clinical assessment.
Consensus criteria were used to classify individuals as:
probable AD (including amnestic, logopenic aphasia,
and posterior cortical atrophy variants) [3]; DLB [7]; be-
havioural variant FTD (bvFTD) [8]; PNFA [8]; and SD
[8, 9]. The diagnosis was confirmed in 20 cases at aut-
opsy; two patients with AD had presenilin 1 mutations,
and three cases of BvFTD had C9ORF72 mutations and
one a Tau mutation. The pre-LP clinical diagnosis (i.e.
without the CSF result) was used for establishing bio-
marker utility. A second neurologist independently
assessed approximately 45% of the cases notes; there
was 95.8% diagnostic agreement between raters.
Validation cohort
All individuals seen in our service who had a diagnostic
CSF examination between 16 May 2013 and 16 May
2016 and who fulfilled consensus criteria for a dementia
diagnosis (as above) were included. Twelve individuals
with an AD diagnosis had an amyloid positron emission
tomography (PET) scan, which was positive in all cases.
Healthy controls
Healthy controls were recruited for research and were
usually partners of affected individuals. No control had a
memory complaint at recruitment or at 1-year follow-up.
Sample treatment and analysis
CSF was collected as previously described [10], i.e. by
LP between 9 am and 3 pm into a polypropylene ves-
sel, centrifuged, and frozen. Samples were thawed at
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the bench for 1 h. The volume of CSF differed be-
tween individuals; accordingly, not all biomarker mea-
surements were made for all members of the test
cohort (see Table 1 for details).
Aβ1–42, T-tau, and P-tau assays were performed in
batches according to local laboratory standard operat-
ing procedures to achieve inter-day coefficients of
variation (CV) < 10%. Other assays (AβX-38, AβX-40
and AβX-42, NFL, YKL-40, sAPPα, and sAPPβ) were
carried out at a single time point in the Neurochem-
istry laboratory of the University of Gothenburg by
board-certified laboratory technicians. We achieved
inter-plate CV of around < 10% for all assays except
sAPPα and sAPPβ (details are provided in Additional
file 1). The validation cohort were tested at the Insti-
tute of Neurology, UCL. Details of the CSF method-
ology are provided in Additional file 1.
Statistical analysis
Analyses were carried out using Stata Version 14.1
(Texas, USA). Data distribution was assessed and
values outside an assay’s reliable detectable range
were assigned maximum/minimum values. Medians
and interquartile ranges were used to describe demo-
graphic and clinical characteristics and CSF biomarker
data by diagnostic group. Missing CSF biomarker
values were assumed to be missing completely at ran-
dom [11], i.e. that the missingness mechanism was
Table 1 Test cohort demographic and biomarker data for all diagnostic groups
AD
(n = 156)
DLB
(n = 20)
bvFTD
(n = 45)
PNFA
(n = 17)
SD
(n = 7)
Controls
(n = 30)
Age at LP (years) 62.5 (57–68) 70.0 (68–75) 61.0 (57–66) 65.0 (61–69) 62.0 (57–68) 63.5 (50–67)
% Male 42.3 75.0 60.0 47.1 71.4 46.7
Symptom onset
to LP (months)
36 (24–60)
(n = 154)
36 (18.5–48) 36 (24–60)
(n = 44)
36 (24–48) 60 (18–72) N/A
MMSE 22 (17–25)
(n = 142)
22 (18–28)
(n = 15)
24 (18–27)
(n = 42)
25 (9.5–28)
(n = 8)
27 (16–27)
(n = 7)
30 (30–30)
Duration of follow-up
(months)
12 (6–24) 11 (4–29.5) 11 (6–23) 12 (4–24) 23 (11–43) N/A
Aβ1–42 (pg/mL) 310.5 (218.0–451.5) 357.5 (327.0–490.0) 638.0 (396.0–871.0) 440.0 (308.0–696.0) 767.0 (633.0–859.0) 953.0 (771.0–1199.0)
T-tau (pg/mL) 674.5 (430.0–973.5) 338.5 (185.0–489.0) 289.0 (187.0–389.0) 501.0 (367.0–744.0) 319.0 (229.0–458.0) 303.5 (189.0–402.0)
T-tau/Aβ1–42 ratio 2.3 (1.2–3.7)
(n = 154)
0.8 (0.4–1.5) 0.4 (0.3–0.7)
(n = 44)
1.1 (0.7–2.1) 0.5 (0.3–0.6) 0.3 (0.2–0.4)
P-tau-181 (pg/L) 86.4 (59.4–111.8)
(n = 119)
47.1 (38.1–64.3)
(n = 16)
49.2 (37.0–64.0)
(n = 39)
62.5 (49.8–100.1)
(n = 13)
50.9 (25.5–58.6) 47.8 (39.3–65.4)
(n = 26)
NFL (ng/L) 1191.5
(857.6–1584.0)
(n = 119)
929.6
(839.9–1650.1)
(n = 17)
1788.4
(839.9–3334.6)
(n = 38)
1974.9
(1627.7–3490.5)
(n = 12)
2400.0
(1687.5–3584.7)
(n = 6)
649.0
(515.9–849.5)
YKL-40 (ng/mL) 163 (127–194)
(n = 114)
158 (134–186
)(n = 16)
163 (135–244)
(n = 35)
192 (140–207)
(n = 10)
179 (132–256)
(n = 5)
111 (93–164)
(n = 29)
AβX-38 (ng/L) 1462.0
(1101.4–2025.5)
(n = 117)
1214.2
(840.1–1529.2)
(n = 15)
1306.0
(1106.2–1658.8)
(n = 34)
1653.8
(1251.7–2046.7)
(n = 12)
1751.4
(1442.0–1777.0)
(n = 5)
2183
(1980.8–3058.6)
(n = 29)
AβX-40 (ng/L) 3635.1
(2911.0–4584.4)
(n = 117)
2916.1
(2235.6–3718.2)
(n = 15)
3439.5
(2714.7–4274.9)
(n = 34)
3900.6
(3175.7–4355.6)
(n = 12)
3965.4
(3702.2–4537.6)
(n = 5)
5478.3
(4888.3–7615.2)
(n = 29)
AβX-42 (ng/L) 164.6 (109.1–231.6)
(n = 117)
182.1 (170.9–281.7)
(n = 15)
284.5 (195.2–369.4)
(n = 34)
183.0 (117.4–343.6)
(n = 12)
346.0 (309.9–372.1)
(n = 5)
592.2 (469.7–749.8)
(n = 29)
AβX-42/X-40 ratio 0.043 (0.036–0.053)
(n = 117)
0.055 (0.047–0.089)
(n = 15)
0.083 (0.072–0.094)
(n = 34)
0.052 (0.040–0.087)
(n = 12)
0.087 (0.085–0.093)
(n = 5)
0.107 (0.092–0.114)
(n = 29)
APPα (ng/mL) 348.8 (254.9–532.7)
(n = 119)
218.6 (175.8–368.1)
(n = 16)
270.7 (164.9–328.7)
(n = 37)
374.3 (316.1–467.3)
(n = 12)
379.5 (281.7–479.8)
(n = 5)
426.4 (322.0–654.5)
APPβ (ng/mL) 202.2 (151.2–325.8)
(n = 119)
138.0 (115.0–175.2)
(n = 16)
128.0 (107.4–187.1)
(n = 37)
220.3 (178.8–298.1)
(n = 12)
181.9 (171.4–236.4)
(n = 5)
258.6 (182.0–372.0)
Median and interquartile ranges are shown
Where data were missing, the number of subjects for which data were available is indicated within parentheses
Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB dementia with Lewy bodies,
LP lumbar puncture, PNFA progressive non-fluent aphasia, SD Semantic dementia, MMSE mini-mental state examination, NFL neurofilament light chain,
P-tau phosphorylated tau, T-tau total tau
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unrelated to any covariates relevant to the analysis.
CSF biomarkers were compared between diagnostic
groups using log-transformed data due to skewed
and/or truncated data, and a generalised least squares
linear regression model was used (an extension of the
t test/analysis of variance (ANOVA) model that allows
different group-specific residual variances). These glo-
bal tests for differences between groups were assessed
first across all groups including healthy controls, then
only in cases with dementia, and finally in cases with
dementia also adjusting for age, sex, and disease dur-
ation. Post-hoc pairwise comparisons between diag-
nostic groups were made when the initial
(unadjusted) global test across dementia-only groups
was statistically significant (p < 0.05), and in any bio-
marker where the unadjusted p value was > 0.05 but
the adjusted p value was < 0.05. For the pairwise
comparisons, a conservative Bonferroni-adjusted
threshold p value for significance (p < 0.003) was also
used, based on 15 pairwise tests for each biomarker.
Non-parametric receiver operating characteristic
(ROC) curves and the area under the curve (AUC)
were used to quantify how well each biomarker dis-
criminated between AD and each other diagnostic
group (or combinations of groups). The group sizes
varied greatly, reflecting the prevalence of these con-
ditions in the population. Assuming that a biomarker
is associated with disease, AUC can be considered a
simple measure of the probability that a randomly se-
lected case would have a higher biomarker value than
a control, assuming higher values are associated with
disease (vice versa if lower values are associated with
disease) [12].
For the five best-performing (based on AUCs) bio-
markers for each of the group comparisons, cut-
points and conservative exact binomial confidence
intervals were estimated for a set sensitivity of 85%,
as suggested by the Reagan consensus report [13],
and the associated specificities calculated. For a set
sensitivity of 85% (i.e. an 85% probability of a positive
test among patients with disease), given that AD is al-
ways set as the ‘case’ in any comparison, the optimal
cut-point for any specific biomarker is the same re-
gardless of which other diagnostic group is being
used as the comparator; it is the specificity that
changes for different comparators.
ROC curves from logistic regression models incorpor-
ating up to five best-performing biomarkers (based on
highest AUC) were used to calculate AUCs where group
sizes were sufficiently large (> 10 subjects in each of two
groups compared) to avoid over-fitting, with bias cor-
rected bootstrapped confidence intervals for the AUC
(2000 replications). The analyses used the ‘leave one out’
approach to address the potential for over-optimistic
estimates of AUCs and specificities obtained from these
joint models, as this can particularly be an issue when
AD cases greatly outnumber the comparator group.
The estimated cut-points of those biomarkers which
showed utility in differentiating AD from one or more
groups in the test cohort, and for which measures were
available, were used to calculate sensitivity and specifi-
city in the validation cohort; due to the small numbers
in some diagnostic groups, we only assessed the ability
to distinguish AD from controls, from other dementias,
and from other dementias and controls combined. Simi-
larly, sensitivity and specificity were calculated in the
pathology/genetically confirmed sub-cohort to distin-
guish AD from other dementias.
Results
Subject demographics
We included 418 subjects, 275 in the test and 143 in
the validation cohorts. The test cohort comprised 245
patients with dementia (AD (n = 156, including 27 pos-
terior cortical atrophy (PCA) and 12 logopenic progres-
sive aphasia (LPA)), DLB (n = 20), bvFTD (n = 45),
PNFA (n = 17), and SD (n = 7)), and 30 controls. All
groups had a similar disease duration (symptom onset
to LP) except for the SD group who presented later
(Table 1). The DLB group was older than the other dis-
ease groups and the proportion of males was higher for
DLB and SD than the other groups. Of the 143 individ-
uals in the validation cohort, 104 had AD, 29 had other
dementias (5 DLB, 12 bvFTD, 3 PNFA, and 9 SD) and
10 were controls.
Pathology and genetic confirmation
In total 26 subjects were pathologically or genetically
confirmed. Eleven subjects in the test cohort who re-
ceived a clinical diagnosis of AD (including two with
PCA) had a pathological diagnosis of AD at autopsy.
None of the subjects diagnosed with AD during life had
a non-AD pathological diagnosis. A further two subjects
had presenilin 1 mutations known to cause AD. One
subject with DLB received a pathological diagnosis of
mixed AD/DLB pathology. Five cases with a clinical
diagnosis of bvFTD received a pathological diagnosis:
one had frontotemporal lobar degeneration with TDP-43
pathology type 3; one had a tauopathy with features
compatible with chronic traumatic encephalopathy; one
had Pick’s disease; one had FTLD-TDP Type A; and one
had mixed AD, Lewy body pathology, and TDP 43 path-
ology. Four further cases had confirmed genetic bvFTD
(three with C9ORF72 mutations and one a Tau muta-
tion). Two patients with PNFA reached autopsy. One
had mixed pathology with Pick’s disease, AD pathology,
cerebral amyloid angiopathy Lewy body pathology and
the other FTLD-TDP Type A pathology. One patient
Paterson et al. Alzheimer's Research & Therapy  (2018) 10:32 Page 4 of 11
with SD received a pathological diagnosis of FTLD-TDP
Type C pathology.
CSF biomarker concentrations
The biomarker profile of each diagnostic group in the
test cohort is shown in Table 1 and box-plots are pro-
vided in Fig. 1. In the validation cohort data were available
for five biomarkers/ratios: Aβ1–42 (n = 143); T-tau (n =
143); P-tau (n = 131); T-tau/Aβ1–42 ratio (n = 143); and
AβX-42/X-40 ratio (n = 140). In the pathology/genetically
confirmed sub-cohort, data were available for: Aβ1–42 (n
= 26); T-tau (n = 26); P-tau (n = 19); T-tau/Aβ1–42 ratio
(n = 26); and AβX-42/X-40 ratio (n = 17).
Comparisons between the groups based on regression
analyses are shown in Table 2. There was a significant
difference (p < 0.05) between disease groups for all
tested biomarkers when controls were included. When
excluding the control group this remained the case for
nine measures. Additionally, when adjusting for age, sex,
and disease duration there was evidence for a difference
(p = 0.04) between groups for one additional biomarker
(YKL-40) whereas no difference had been apparent in
the unadjusted analysis (p = 0.51).
Figure 1 shows pairwise comparisons between diag-
nostic groups where the (unadjusted) global test across
dementia-only groups was statistically significant (un-
adjusted p < 0.05). A summary of where there was evi-
dence of a difference in mean biomarker concentration
is shown in Table 3 for each pairwise comparison, both
for an unadjusted p < 0.05 threshold for significance and
a conservative Bonferroni-adjusted p < 0.003 threshold.
Based on the conservative Bonferroni-adjusted thresh-
old for significance, T-tau/Aβ1–42 ratio, T-tau, and P-
tau were significantly elevated in AD compared with
Fig. 1 Box-plots and whiskers (25th–75th percentiles) and outliers of measured biomarker concentrations presented by disease group (pre-lumbar
puncture diagnosis) and unadjusted pairwise comparisons (p-values). X-axis: pre-lumbar puncture diagnosis. Aβ amyloid beta, AD Alzheimer’s
disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB Lewy body dementia, HC healthy controls,
NFL neurofilament light chain, PNFA progressive non-fluent aphasia, P-tau phosphorylated tau, SD semantic dementia, T-tau total tau
Paterson et al. Alzheimer's Research & Therapy  (2018) 10:32 Page 5 of 11
each of the other neurodegenerative disorders tested, ex-
cept PNFA. AβX-42/AβX-40 was significantly lower in
the AD cohort than in bvFTD and SD. Aβ1–42 concen-
trations were lowest in the AD and DLB groups; there
was no evidence this biomarker differed between these
two disease groups. NFL was significantly higher in all
neurodegenerative disorders compared with healthy con-
trols (Fig. 1); concentrations were higher in the SD and
PNFA groups compared with the AD group (Table 3).
APPα and APPβ were significantly lower in bvFTD com-
pared with AD, PNFA, and healthy controls (Fig. 1).
AβX-38 and AβX-40 concentrations were lower in all
neurodegenerative diseases, except SD, compared with
controls (p < 0.001) but there were no pairwise signifi-
cant differences between each of the diseases. YKL-40
concentrations were higher across all dementias relative
to healthy controls but not between diseases in the un-
adjusted analyses; after adjusting for age, sex, and time
from symptom onset to LP there was evidence of a dif-
ference between DLB and bvFTD (p = 0.003).
Diagnostic utility of CSF biomarkers
Cut-points for each biomarker at a pre-determined fixed
sensitivity of 85% are shown in Table 4. A summary of the
‘top 5’ biomarkers (by AUC) is given in Table 5, with the
highest AUCs varying between 0.79 and 0.95; the specific-
ities are also shown and varied between 24% and 100%.
Table 5 also shows the results from incorporating the
best-performing biomarkers into a single model for each
of the comparisons of AD against other groups. There
was no suggestion that including more than one bio-
marker usefully improved AUC or specificity when com-
pared to the single biomarker with highest AUC or
specificity, respectively.
Table 2 Regression analyses comparing biomarkers between all
disease groups classified according to pre-lumbar puncture
diagnosis, with and without healthy controls
Global test*
including HC
(p value)
Global test**
excluding HC
(p value)
Adjusted***
global test
excluding HC
(p value)
Aβ1–42 < 0.0001 < 0.0001 < 0.0001
T-tau < 0.0001 < 0.0001 < 0.0001
T-tau/Aβ1–42 ratio < 0.0001 < 0.0001 < 0.0001
P-tau-181 < 0.0001 < 0.0001 < 0.0001
NFL < 0.0001 < 0.0001 < 0.0001
YKL-40 0.0038 0.51 0.04
AβX-38 < 0.0001 0.43 0.17
AβX-40 < 0.0001 0.57 0.30
AβX-42 < 0.0001 0.0001 0.0002
AβX-42/X-40 ratio < 0.0001 < 0.0001 < 0.0001
APPα < 0.0001 < 0.0001 0.0001
APPβ < 0.0001 0.0001 0.0001
Biomarker data are log transformed to achieve normal distribution
Aβ amyloid beta, APP amyloid precursor protein, HC healthy controls,
NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
*p < 0.05 provides evidence that the disease groups, including the HC group,
do not all have the same mean biomarker value
**As for *, excluding control group
***As for **, also adjusting for age, sex, and time from symptom onset to
lumbar puncture
Table 3 Summary of the biomarkers that are significantly different between neurodegenerative disorders
Aβ1–42 T-tau T-tau/Aβ1–42 P-tau NFL AβX-42 AβX-42/X-40 APPα APPβ
AD vs DLB +
++
+
++
+
++
+ + +
AD vs bvFTD +
++
+
++
+++ +
++
+ +
++
+
++
+
++
+
++
AD vs PNFA + + +
++
AD vs SD +
++
+
++
+
++
+
++
+
++
+
++
+
++
DLB vs bvFTD +
++
+ +
DLB vs PNFA + + + + +
DLB vs SD +
++
+ + + +
bvFTD vs PNFA +
++
+
++
+ + +
++
+
++
bvFTD vs SD
PNFA vs SD + + +
++
+ +
Biomarkers with “+” distinguish between groups with p < 0.05 from the unadjusted analysis, and “++” distinguish between groups with Bonferroni corrected p < 0.003
Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB dementia with Lewy bodies,
PNFA progressive non-fluent aphasia, SD Semantic dementia, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
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Validation
In the validation cohort we calculated sensitivity and spe-
cificity for Aβ1–42, T-tau, P-tau, T-tau/Aβ1–42, and AβX-
42/X-40 using the optimal cut-points determined in the
test cohort that provided a sensitivity of 85% (Additional
file 2: Table S1). Sensitivities were very consistent with the
85%, ranging from 83 to 88% for all biomarkers compared
between all groups except for Aβ1–42 where the sensitiv-
ity was lower (71%). We also calculated sensitivities and
specificities of these biomarkers for the pathologically or
genetically defined cases (n = 26) (Additional file 2: Table
S1), finding superior sensitivities (83–100%) and broadly
comparable specificities given the smaller sample sizes
and missing values for some biomarkers.
Discussion
In this single centre, primarily clinic-based study we
show that some biomarkers with proven ability to distin-
guish AD from healthy controls [2] also have utility for
differentiating AD from other neurodegenerative demen-
tias in clinical practice. In particular, T-tau/Aβ1–42 and
AβX-42/X-40 ratios combine high sensitivity (85%) and
good specificity (> 70%) for distinguishing AD not only
from controls but also from SD and bvFTD; Aβ1–42
performed similarly well for distinguishing AD from
controls and SD. In contrast, none of the biomarkers, or
models with multiple biomarkers, could reliably differen-
tiate AD from DLB or PNFA with high specificity.
The cut-points we generated are similar to those found
in other studies. For differentiating AD subjects from
healthy controls we found broad agreement with those
reported in previous studies [14] for Aβ1–42, T-tau/
Aβ1–42, and AβX-42/X-40. The exception was P-tau,
where our cut-point (48.9 pg/mL) was lower than that
quoted by the kit manufacturer (61 pg/mL) [15]. This
may reflect our choice of a set sensitivity of 85% (result-
ing in a specificity of 54%) compared with the manufac-
turer’s 80% (with a specificity of 87%).
Overall, we found no evidence that models incorporat-
ing multiple biomarkers (or simple ratios) materially
improved AUC or specificity compared to the best-
performing single biomarker (or ratio) with highest AUC
or specificity, respectively. Specifically, for AD vs healthy
controls we were able to achieve good sensitivity and
specificity using Aβ1–42, T-tau/Aβ1–42, and AβX-42/X-
40 without using complex models of multiple bio-
markers or formulae that have been proposed in other
studies [16, 17].
It was possible to differentiate AD from SD or bvFTD
with good sensitivity and specificity particularly using
AβX-42/X-40. While the 100% specificity for AβX-42/X-
40 to distinguish AD from SD is inevitably influenced by
the small SD sample size, the generally high specificities
are likely to reflect that SD is very pathologically homo-
geneous, typically being underpinned by TDP 43 type C
pathology [18, 19] as was the case in the one SD case in
this cohort who came to autopsy. Using AβX-42/X-40,
the specificity for AD versus bvFTD was still high (85%)
despite the fact that bvFTD can sometimes be caused by
AD pathology, or have co-existent AD pathology [19].
We found that no single or ratio of CSF biomarkers
achieved useful specificity for distinguishing AD from
DLB [20, 21]. P-tau and T-tau were the best performing
biomarkers but, consistent with a previous meta-analysis
[22], they were not diagnostically useful, achieving speci-
ficities of only approximately 50%. This is likely to
reflect that AD pathology is very common in pathologic-
ally confirmed DLB [23], as was seen in the one subject
in this cohort with clinically diagnosed DLB who had
mixed AD/DLB pathology at autopsy. Improving specifi-
city is therefore likely to require a positive biomarker for
DLB pathology, e.g. a reliable marker of alpha-synuclein
inclusions. An enzyme-linked immunosorbent assay
(ELISA) biomarker for DLB pathology has slightly
improved the diagnostic utility of CSF biomarkers for
differentiating AD from DLB [24]; more recently, a real-
time quaking induced conversion assay (RT-QUIC)
showed significant promise as a highly specific test for
DLB pathology [25].
None of the biomarkers was useful for differentiating
AD from PNFA; the best performing measure was NFL,
which achieved a specificity of only 50%. PNFA is clas-
sically considered within the FTD spectrum, but 10–30%
of cases have AD pathology at autopsy [26, 27]. In this
cohort two PNFA case had had an autopsy, where mixed
pathology (Pick’s disease, AD, cerebral amyloid angiopa-
thy, and Lewy Body pathology) and FTLD TDP 43 path-
ology were found. The relatively poor specificity for any
CSF biomarker in this group is likely therefore to reflect
Table 4 Optimal cut-point (95% CI) for AD* at a sensitivity of 85%
Biomarker Cut-point 95% CI
Lower Upper
Aβ1–42 (pg/mL) < 529.0 479.0 647.0
T-tau (pg/mL) > 312.0 261.0 391.0
T-tau/Aβ1–42 ratio > 0.64 0.52 1.01
P-tau (pg/L) > 48.9 42.4 58.7
AβX-42/X-40 < 0.060 0.055 0.088
APPβ (ng/mL) > 136.4 115.3 144.6
NFL (ng/L) < 1877.0 609.8 3149.6
*For a set sensitivity of 85%, given that AD is always set as the ‘case’ in any
comparison, the optimal cut-point for any specific biomarker is the same
regardless of which other diagnostic group is being used as the comparator;
it is the specificity that changes for different comparators
Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein,
CI confidence interval, NFL neurofilament light chain, P-tau phosphorylated
tau, T-tau total tau
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Table 5 AUC (and 95% CI) and specificity (at a fixed sensitivity of 85%) of the ‘top 5’ biomarkers, comparing AD with other
neurodegenerative disorders and controls
Diagnostic groups Biomarker AUC (95% CI) Specificity (%)*
AD vs HC AβX-42/X-40 ratio 0.95 (0.92–0.99) 93%
Aβ1–42 (pg/mL) 0.93 (0.88–0.98) 90%
T-tau/Aβ1–42 ratio 0.93 (0.89–0.97) 83%
T-tau (pg/mL) 0.81 (0.73–0.90) 53%
P-tau (pg/L) 0.80 (0.71–0.88) 54%
All the above 0.91 (0.84–0.95) 88%
AD vs DLB P-tau (pg/L) 0.79 (0.68–0.90) 50%
T-tau (pg/mL) 0.78 (0.67–0.88) 50%
T-tau/Aβ1–42 ratio 0.77 (0.66–0.88) 40%
AβX-42/X-40 ratio 0.73 (0.59–0.88) 47%
APPβ (ng/mL) 0.73 (0.58–0.87) 44%
All the above 0.75 (0.54–0.88) 50%
AD vs bvFTD T-tau/Aβ1–42 ratio 0.89 (0.85–0.94) 70%
AβX-42/X-40 ratio 0.86 (0.77–0.94) 85%
T-tau (pg/mL) 0.83 (0.76–0.90) 64%
Aβ1–42 (pg/mL) 0.78 (0.70–0.87) 60%
P-tau (pg/L) 0.78 (0.70–0.86) 46%
All the above 0.86 (0.78–0.92) 81%
AD vs PNFAa NFL (ng/L) 0.84 (0.76–0.93) 50%
T-tau/Aβ1–42 ratio 0.67 (0.54–0.80) 24%
Aβ1–42 (pg/mL) 0.65 (0.50–0.80) 35%
All the above 0.60 (0.16–0.76) 42%
AD vs SDb AβX-42/X-40 ratio 0.92 (0.86–0.97) 100%
T-tau/Aβ1–42 ratio 0.91 (0.86–0.96) 86%
Aβ1–42 (pg/mL) 0.91 (0.84–0.98) 86%
NFL (ng/L) 0.87 (0.78–0.96) 67%
P-tau (pg/L) 0.85 (0.75–0.94) 29%
AD vs non-AD dementia T-tau/Aβ1–42 ratio 0.82 (0.77–0.88) 56%
AβX-42/X-40 ratio 0.79 (0.72–0.87) 68%
T-tau (pg/mL) 0.77 (0.71–0.83) 51%
P-tau (pg/L) 0.76 (0.70–0.83) 41%
Aβ1–42 (pg/mL) 0.73 (0.67–0.80) 48%
All the above 0.81 (0.73–0.85) 68%
AD vs all others (including HC) T-tau/Aβ1–42 ratio 0.85 (0.80–0.90) 63%
AβX-42/X-40 ratio 0.84 (0.79–0.90) 76%
T-tau (pg/mL) 0.78 (0.73–0.84) 51%
Aβ1–42 (pg/mL) 0.78 (0.73–0.84) 59%
P-tau (pg/L) 0.77 (0.71–0.83) 45%
All the above 0.84 (0.79–0.90) 75%
Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, AUC area under the curve, bvFTD behavioural variant frontotemporal dementia,
CI confidence interval, DLB dementia with Lewy bodies, HC healthy controls, PNFA progressive non-fluent aphasia, SD Semantic dementia, NFL neurofilament light
chain, P-tau phosphorylated tau, T-tau total tau
aOnly three biomarkers were found to be significant, see Table 3
bThere is no joint model for AD vs SD because n < 10 for SD
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cases of PNFA due to AD, and PNFA with mixed AD
pathology, and emphasizes the need for pathology-
specific biomarkers for the non-AD dementias.
While T-tau/Aβ1–42 ratio performed well in several
of the disease group comparisons, neither T-tau nor P-
tau was diagnostically useful alone, conferring specific-
ities of at most 64%. CSF Aβ1–42 alone was relatively
poor at distinguishing AD from other neurodegenera-
tive disorders (except for SD), in line with other
studies [22]. Specificity was, however, consistently im-
proved using the AβX-42/X-40 ratio [28–30]. AβX-40
is the most abundant soluble Aβ peptide and less likely
than Aβ1–42 to aggregate, and thus incorporating both
in a ratio may account for inter-individual physio-
logical differences in amyloid processing [31]. AβX-42/
X-40 ratio performed at least as well as T-tau/Aβ1–42
ratio; adding T-tau to AβX-42/X-40 did not improve
specificity, suggesting that the AβX-42/X-40 ratio
alone may a reliable means of identifying brain amyloid
deposition.
While the focus of the study was on differentiating AD
from other dementias, a number of potentially interest-
ing findings emerge from some of the more novel bio-
markers. Our finding that NFL concentration was
highest in SD is consistent with a number of previous
studies [32–34]. NFL is thought to be a marker of large
axonal neurodegeneration [35] and is elevated in a num-
ber of non-AD diseases [36–38], particularly FTD and
motor neurone disease [39]. We found that the concen-
tration of YKL-40 was elevated in AD compared to con-
trols, in keeping with prior studies [2, 40]. We did not
find either APPα or APPβ to be useful in differentiating
AD from controls.
This study has a number of caveats. We used clinical
diagnosis based on a blinded independent assessment
using contemporary clinical criteria to establish the diag-
nosis, rather than post-mortem confirmation of under-
lying pathology or pathologies. Very few CSF studies in
dementia have pathological confirmation of diagnosis,
and this is therefore a limitation of most work in the lit-
erature. However, we were able to confirm a definite
pathological or genetic diagnosis in 26/245 subjects with
dementia in the test cohort. In cases fulfilling clinical
criteria for AD, approximately 10% had either patho-
logical confirmation, genetic confirmation, or supportive
amyloid imaging, with no false positive diagnoses. Simi-
larly, bvFTD and SD diagnoses were supported by
pathological confirmation in approximately 10% of cases
with all having FTD pathology or mixed FTD/AD
pathology.
There is not perfect concordance between clinical
diagnosis and underlying pathology, and this varies
considerably depending on the clinical syndrome. In
patients diagnosed with probable AD, the sensitivity
and specificity for underlying AD pathology are in the
order of approximately 75% and 60%, respectively [41].
AD pathology is found in approximately 55% of cases
of DLB [42], approximately 40% of PNFA cases [43], 5–
6% of bvFTD [44], and between 0 and 15% of SD cases
[19, 45, 46]. The results in this study are broadly consistent
with these figures; indeed, the best specificity found for
each group is strikingly similar to the proportion who
would be expected not to have AD pathology at post
mortem (SD 100%, bvFTD 85%, PNFA 50%, DLB 50%).
This is therefore consistent with our interpretation that
current biomarkers are good at distinguishing AD from
syndromes that are not usually caused by AD (e.g. SD
and bvFTD) but not from those commonly caused by
AD (PNFA) or where there is AD co-pathology (DLB).
The number of samples in some groups was compara-
tively small, particularly in the rarer clinical syndromes,
but are likely to represent the proportion of patients
who might undergo diagnostic CSF examination. There
is no optimal means of determining biomarker cut-
points [12], but we used a consistent and recommended
method of fixing sensitivity at 85%. There was variability
in the inter-plate variability depending on the analyte
measured. While most assays achieved inter-day and
inter-plate variability of < 10%, we acknowledge that the
inter-plate CV for the APP ELISA assays were > 10% and
results should be interpreted with caution. Finally, while
we used an extended CSF panel, this was not compre-
hensive and did not for example include neurogranin,
which may have good specificity for AD [47].
Conclusions
Biomarkers in routine clinical use (particularly AβX-
42/X-40 and T-tau/Aβ1–42 ratios) not only have util-
ity in distinguishing AD from controls, but also from
bvFTD and SD. These measures, and the other bio-
markers tested, have less utility in differentiating AD
from DLB and PNFA, likely reflecting varying degrees
of AD (amyloid) pathology in these conditions. This
study provides an evidence base for the use of CSF
biomarkers for the differential diagnosis of AD, high-
lights the potential utility of the AβX-42/X-40 ratio,
and shows that novel biomarkers specific for other
non-AD disorders are required.
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